Epizyme

📍 Cambridge, United States🗓 Founded 2007👥 249 employees💰 Last funded May 2013
Biotechnology🌐 epizyme.com
Website LinkedIn
Epizyme, Inc. is a late-stage biopharmaceutical company rewriting therapy for cancer and other serious diseases through novel epigenetic medicines. Our pipeline is led by tazemetostat, an investigational agent that is an orally administered, first-in-class small molecule EZH2 inhibitor for the treatment of multiple types of hematological malignancies and genetically defined solid tumors. The company also is developing a novel G9a program with its next development candidate, EZM8266, which is targeting sickle cell disease. By focusing on the genetic drivers of disease, Epizyme's science seeks to match targeted medicines with the patients who need them. For more information, visit www.epizyme.com.
2
Total investors
1
Early stage
0
Mid stage
0
Late stage
2007
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Epizyme?
Epizyme has 2 investors on record on gritt.io, including 1 early-stage backers.
When did Epizyme last raise funding?
The most recent investment in Epizyme recorded on gritt.io was in May 2013.
When was Epizyme founded?
Epizyme was founded in 2007.
What industry is Epizyme in?
Epizyme operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Epizyme based?
Epizyme is headquartered in Cambridge, United States.